Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results
-
Revenue: Q4 2023 collaboration revenue was $15.2 million, with a full-year total of $97.1 million.
-
R&D Expenses: Q4 2023 research and development expenses decreased to $47.7 million from $54.5 million in Q4 2022.
-
G&A Expenses: Q4 2023 general and administrative expenses were $14.9 million, down from $15.4 million in Q4 2022.
-
Net Loss: Q4 2023 net loss improved to $41.4 million, or $0.49 per share, from a net loss of $52.4 million, or $0.63 per share, in Q4 2022.
-
Cash Position: Pro forma cash, cash equivalents, and investments totaled $620.0 million after January 2024 equity offering.
-
2024 Guidance: Anticipated collaboration revenue between $60 million and $70 million, with R&D expenses between $210 million and $230 million, and G&A expenses between $60 million and $70 million.
On February 27, 2024, Alector Inc (NASDAQ:ALEC), a clinical-stage biopharmaceutical company focused on immuno-neurology, released its 8-K filing, detailing its financial results for the fourth quarter and the full year of 2023. The company, known for developing therapies to counteract neurodegenerative pathologies by restoring healthy immune function to the brain, has reported significant clinical progress alongside its financial outcomes.
Financial Performance and Clinical Progress
Alector's financial position remains robust, with a cash runway extended through 2026, thanks to a successful January 2024 equity offering. The company's collaboration revenue for Q4 2023 was $15.2 million, a slight increase from $14.4 million in the same period of the previous year. However, full-year collaboration revenue saw a decrease from $133.6 million in 2022 to $97.1 million in 2023, primarily due to the termination of the AL003 program in 2022.
Research and development expenses for Q4 2023 were $47.7 million, down from $54.5 million in Q4 2022, reflecting Alector's strategic focus on advancing late-stage clinical programs. General and administrative expenses also saw a decrease, from $15.4 million in Q4 2022 to $14.9 million in Q4 2023, attributed to lower consulting and insurance costs.
The net loss for Q4 2023 improved to $41.4 million, or $0.49 per share, compared to a net loss of $52.4 million, or $0.63 per share, for the same period in 2022. For the full year, the net loss was $130.4 million, or $1.56 per share, slightly better than the $133.3 million, or $1.62 per share, reported for 2022.
Strategic Clinical Developments
Alector's clinical advancements include the completion of enrollment for the INVOKE-2 Phase 2 trial of AL002 and the pivotal INFRONT-3 Phase 3 trial of latozinemab. The FDA granted Breakthrough Therapy Designation to latozinemab for frontotemporal dementia due to a mutation in the progranulin gene (FTD-GRN), recognizing the urgent need for treatment options.